These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8296491)

  • 61. Hormonal, metabolic and clinical effects of danazol in the treatment of endometriosis.
    Rannevik G
    Postgrad Med J; 1979; 55 Suppl 5():14-20. PubMed ID: 537948
    [TBL] [Abstract][Full Text] [Related]  

  • 62. An open and randomized study comparing the efficacy of standard danazol and modified triptorelin regimens for postoperative disease management of moderate to severe endometriosis.
    Wong AY; Tang L
    Fertil Steril; 2004 Jun; 81(6):1522-7. PubMed ID: 15193471
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
    Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
    Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
    Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of the suppressive capacity of different depot gonadotropin-releasing hormone analogs in women.
    Filicori M; Flamigni C; Cognigni G; Dellai P; Arnone R; Falbo A; Capelli M
    J Clin Endocrinol Metab; 1993 Jul; 77(1):130-3. PubMed ID: 8325935
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Gonadotropin-releasing agonist in the therapy of patients with laparoscopically confirmed endometriosis].
    Pŭnevska M; Filipov E; Nalbanski A; Nalbanski B
    Akush Ginekol (Sofiia); 2004; 43 Suppl 4():58-60. PubMed ID: 15673017
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Aromatase inhibitors prevent the estrogen rise associated with the flare effect of gonadotropins in patients treated with GnRH agonists.
    Bedaiwy MA; Mousa NA; Casper RF
    Fertil Steril; 2009 Apr; 91(4 Suppl):1574-7. PubMed ID: 18973892
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment.
    Paoletti AM; Serra GG; Cagnacci A; Vacca AM; Guerriero S; Solla E; Melis GB
    Fertil Steril; 1996 Apr; 65(4):707-10. PubMed ID: 8654625
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Successful treatment of refractory endometriosis-related chronic pelvic pain with aromatase inhibitors in premenopausal patients.
    Verma A; Konje JC
    Eur J Obstet Gynecol Reprod Biol; 2009 Apr; 143(2):112-5. PubMed ID: 19233536
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Absence of immunoreactive luteinizing hormone following gonadotropin-releasing hormone agonist therapy in women with endometriosis.
    Bischof P; Herrmann WL
    Gynecol Obstet Invest; 1988; 25(2):130-4. PubMed ID: 2967234
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Treatment of endometriosis with domestic luteinizing hormone--releasing hormone analogue].
    Geng L; Gu FY; Zhang LZ
    Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):592-4, 636. PubMed ID: 7712871
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Differences in serum LH and FSH levels using depot or daily GnRH agonists in controlled ovarian stimulation: influence on ovarian response and outcome of ART.
    Sonntag B; Kiesel L; Nieschlag E; Behre HM
    J Assist Reprod Genet; 2005 Aug; 22(7-8):277-83. PubMed ID: 16195824
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Hormonal changes in buserelin therapy].
    Fuchs U; Zwirner M
    Zentralbl Gynakol; 1989; 111(18):1236-40. PubMed ID: 2511705
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evaluation of oral medroxyprogesterone acetate in the treatment of endometriosis.
    Luciano AA; Turksoy RN; Carleo J
    Obstet Gynecol; 1988 Sep; 72(3 Pt 1):323-7. PubMed ID: 2970029
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Menstrual cycle synchronization, ovarian stimulation, and in vitro fertilization in olive baboons (Papio anubis): a prospective randomized study.
    Nyachieo A; Spiessens C; Chai DC; Mwenda JM; D'Hooghe TM
    Fertil Steril; 2009 Feb; 91(2):602-10. PubMed ID: 18328482
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Induction of hot flashes in premenopausal women treated with a long-acting GnRH agonist.
    DeFazio J; Meldrum DR; Laufer L; Vale W; Rivier J; Lu JK; Judd HL
    J Clin Endocrinol Metab; 1983 Mar; 56(3):445-8. PubMed ID: 6401756
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A 6-Month Trial of the Efficacy and Safety of Triptorelin Pamoate (11.25 mg) Every 3 Months in Children with Precocious Puberty: A Retrospective Comparison with Triptorelin Acetate.
    Zenaty D; Blumberg J; Liyanage N; Jacqz-Aigrain E; Lahlou N; Carel JC;
    Horm Res Paediatr; 2016; 86(3):188-195. PubMed ID: 27603324
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Low dose intranasal nafarelin for the treatment of endometriosis.
    Jacobson J; Harris SR; Bullingham RE
    Acta Obstet Gynecol Scand; 1994 Feb; 73(2):144-50. PubMed ID: 8116353
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Treatment of Endometriosis with the GnRHa Deslorelin and Add-Back Estradiol and Supplementary Testosterone.
    Agarwal SK; Daniels A; Drosman SR; Udoff L; Foster WG; Pike MC; Spicer DV; Daniels JR
    Biomed Res Int; 2015; 2015():934164. PubMed ID: 26881208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.